Добро пожаловать
Вход / Регистрация
Стоматология Совершенная Улыбка, метро Свиблово ежедневно с 9-00 до 21-00 скидки по купону на сайте: http://perfect-dent.ru/sale

Healthcare Stocks: Can UnitedHealth J&J Keep Winning?

Воспроизведение вашего видео начнется через 5
Стоматология Совершенная Улыбка, метро Свиблово, ежедневно с 9-00 до 21-00 скидки по купону на сайте: http://perfect-dent.ru/sale

Спасибо! Поделитесь с друзьями!

URL

Вам не понравилось видео. Спасибо за то что поделились своим мнением!

Sorry, only registred users can create playlists.
URL


Добавлено by Admin В Стоматология будущего
1 Просмотры

Описание

UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) are two of the stock market's biggest companies and last quarter, each delivered better financial results than industry-watchers were expecting. In this episode of The Motley Fool's Industry Focus: Healthcare, hosy Shannon Jones and Motley Fool contributor Todd Campbell dig into the details to explain what was behind their better-than-expected results and what investors ought to be watching from here. In the show, they discuss:

What caused J&J's consumer goods business to grow;
Why oncology is so important to J&J's future;
The multibillion dollar drug that could dent J&J's sales in 2019;
How Medicare and Medicaid are boosting UnitedHealth's sales;
And, the tailwinds supporting UnitedHealth's insurance and analytics business.

Additionally, Jones and Campbell explain how Genfit, a small French biotech company, hopes to outmaneuver large competitors like Gilead Sciences (NASDAQ: GILD) in non-alcoholic steatohepatitis, a potential $35 billion market.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts

Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool

Написать комментарий

Комментарии

Комментариев нет.
RSS